Jia-Ying Zhou

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma

X. Yi, Yi-long Wu, W. Zhong, 2020, EBioMedicine.

Prediction of unfavourable response to checkpoint blockade in lung cancer patients through an integrated tumour-immune expression score

Yi-long Wu, Jin-Ji Yang, K. Yin, 2021, Translational oncology.

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2021, Experimental Hematology & Oncology.

Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer

Yi-long Wu, S. Liu, Jia-Ying Zhou, 2020, Expert opinion on drug safety.

Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients

Yi-long Wu, Jin-Ji Yang, Y. Shao, 2020, Biomarker Research.

Concomitant genetic alterations having greater impact on the clinical benefit of EGFR‐TKIs in EGFR‐mutant advanced NSCLC than BIM deletion polymorphism

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2020, Clinical and translational medicine.

Experimental warming changed reproductive phenology and height of alpine plants on the Qingzang Plateau

Zhen-Hua Zhang, Jia-Ying Zhou, Yao Wei, 2022, Chinese Journal of Plant Ecology.